Duration: 2021 – 2025
Consortium: Open Evidence (partner), UPORTO (lead), UPM, EMP, UiO, CERTH, TiU, APDP, FISM, ECHA, SERMAS, UDGA, AHUS, UPPMD, MEDIDA, INS, UHC, MYS Astellas, Janssen, Link2Trials, Merck, Novo Nordisk, Pfizer, Resmed, Servier, Takeda
Methodology: Behavioural Study
Tools: Literature Review, Interviews, Focus Groups, Behavioural Experiments, Surveys, Workshop, Data Analysis, Case Studies, Modelling,
Fieldwork: Norway, Spain, the Netherlands, Germany, Portugal, Italy
Geographical scope: Global
Adherence to treatment is important for full benefit of treatment and therapy, and the key factor for a variety of subsequent health outcomes. The main objective of this project is to create BEAMER, a disease-agnostic behavioral and adherence model for improving quality, health outcomes and cost-effectiveness of healthcare, through improving the quality of life of individuals, enhance healthcare accessibility and sustainability. The model allows for tailoring to individuals’ needs, using Real World Data captured from patients’ behaviors and health system information, transforming the way healthcare stakeholders engage with patients to optimize understanding of their condition and adherence levels throughout their patient journey. BEAMER is driven by a set of Ontology, Epistemology and Methodology principles, supported by Artificial Intelligence, Natural Language Processing, and Machine Learning. The developed disease-agnostic adherence modelis optimized by real-life testing proof-of-concept in 18 different pilots in multiple European countries, including over 18,000 patients (3000 patients in each thematic area). BEAMER will be embodied in an open source European searchable database, continuously updated, validated and optimized by empirical evidence and new insights, available to all stakeholders and adaptable for future developments in healthcare.